Welcome to our dedicated page for HCA Healthcare SEC filings (Ticker: HCA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HCA Healthcare filings document a NYSE-listed healthcare services company whose common stock is registered under Section 12(b) and whose wholly owned subsidiary, HCA Inc., issues senior unsecured notes guaranteed by the parent. Recent 8-K reports record quarterly operating results, dividends, share repurchase authorization, commercial paper and debt refinancing activity, and indenture supplements for senior notes.
Proxy and annual-meeting disclosures cover director elections, shareholder voting results, board matters, executive compensation, and performance award programs linked to EBITDA and quality measures. Registration and offering-related filings describe shelf registration use, prospectus supplements, note terms, guarantees, trustee arrangements and capital-structure disclosures for HCA's healthcare services operations.
MICHELSON MICHAEL W reported acquisition or exercise transactions in this Form 4 filing.
HCA Healthcare director Michael W. Michelson reported a grant of 925 shares of common stock-equivalent restricted share units as director compensation. These include 509 units from an annual director equity award and 416 units received instead of cash retainers for his director and independent presiding director roles.
The restricted share units will vest on the earlier of the date of HCA Healthcare’s 2027 annual shareholders’ meeting or the first anniversary of the grant date. The vested shares will be delivered when Michelson ceases to serve on the company’s Board of Directors. After this grant, he directly holds 12,576 shares of common stock.
Johnston Hugh F reported acquisition or exercise transactions in this Form 4 filing.
HCA Healthcare director Hugh F. Johnston received an equity grant of 809 shares of common stock. The award represents restricted share units tied to his annual director equity grant and to receiving his annual cash retainer in stock rather than cash.
The filing states that 509 restricted share units relate to an annual director equity award and 300 restricted share units are in lieu of an annual cash retainer. These units will vest on the earlier of the 2027 annual shareholders' meeting or the first anniversary of the grant date. Vested shares will be delivered when Johnston ceases to serve on HCA Healthcare's Board of Directors, and his direct holdings total 4,475 shares after this grant.
DEPARLE NANCY ANN reported acquisition or exercise transactions in this Form 4 filing.
HCA Healthcare, Inc. director Nancy Ann DeParle reported receiving an equity award of 509 shares of common stock in the form of restricted share units, granted at a price of $0.00 per share as compensation rather than an open-market purchase. According to the footnote, these 509 restricted share units vest on the earlier of the company’s 2027 annual shareholders’ meeting or the first anniversary of the grant date. Following this award, DeParle directly holds a total of 21,910 shares of HCA Healthcare common stock.
CHIDSEY JOHN reported acquisition or exercise transactions in this Form 4 filing.
HCA Healthcare director John Chidsey reported an equity award of 809 restricted share units of common stock. These units were granted as part of his annual director compensation, including 509 units from an annual director equity award and 300 units received in lieu of an annual cash retainer.
Following this grant, Chidsey directly holds 1,305 shares of HCA Healthcare common stock. In addition, 25 shares are held indirectly by his spouse, and 3 shares are held in a fully managed account over which he does not have investment authority and for which he disclaims beneficial ownership except for any pecuniary interest.
HCA Healthcare, Inc. reported that its subsidiary HCA Inc. has completed a public debt offering of $3.0 billion in senior unsecured notes, all guaranteed by HCA Healthcare on a senior unsecured basis. The offering consists of $1.0 billion of 4.700% Senior Notes due May 15, 2031, $750 million of 5.000% Senior Notes due May 15, 2033, and $1.25 billion of 5.300% Senior Notes due May 15, 2036, issued under an existing base indenture and new supplemental indentures.
Interest on each series is payable semi-annually on May 15 and November 15, beginning November 15, 2026, to holders of record as of May 1 or November 1. The notes rank as senior unsecured obligations of HCA Inc., are fully and unconditionally guaranteed by HCA Healthcare, and are subject to covenants that limit certain liens, sale-leaseback transactions, and major corporate restructurings. HCA Inc. may redeem some or all of the notes at specified redemption prices, and on a qualifying change of control combined with ratings downgrade, holders can require HCA Inc. to repurchase their notes at 101% of principal plus accrued interest.
HCA Healthcare Inc ownership filing shows Vanguard Capital Management beneficially owned 11,746,315 shares of common stock, representing 5.25% of the class as of 03/31/2026. The filing reports sole dispositive power for 11,746,315 shares and sole voting power for 1,567,953 shares. The Schedule 13G is signed on 04/30/2026 by Ashley Grim.
HCA Inc. is offering $3,000,000,000 aggregate principal amount of senior notes: $1,000,000,000 4.700% notes due May 15, 2031, $750,000,000 5.000% notes due May 15, 2033, and $1,250,000,000 5.300% notes due May 15, 2036. Interest on each series is payable semi‑annually on May 15 and November 15, beginning November 15, 2026.
HCA intends to use net proceeds (estimated at $2.975 billion) to redeem in full its outstanding $1.500 billion 5.250% notes due June 2026 and $1.000 billion 5.375% notes due September 2026 and for general corporate purposes, which may include repayment of commercial paper. The notes are senior unsecured obligations of HCA Inc. and are guaranteed on a senior unsecured basis by HCA Healthcare, Inc.
HCA Healthcare’s first quarter of 2026 showed steady growth with rising capital returns but a tougher payer mix. Revenue increased 4.3% to $19.109 billion, driven by a 1.1% rise in equivalent admissions and a 3.1% increase in revenue per equivalent admission. Net income attributable to HCA inched up to $1.620 billion, while diluted EPS rose to $7.15 from $6.45, helped by share repurchases that reduced diluted shares to 226.652 million.
Operating cash flow strengthened to $2.014 billion from $1.651 billion, supporting $1.119 billion of capital spending and $1.571 billion of share repurchases for 3.157 million shares. However, the cost of total uncompensated care grew to an estimated $1.252 billion from $1.055 billion as uninsured admissions climbed following the expiration of enhanced premium tax credits. Total debt reached $48.023 billion, much of it long term, and HCA continued its dividend program, with a $0.78 per-share quarterly dividend declared for payment in June 2026.
HCA Healthcare, Inc. reported the results of its Annual Meeting of Stockholders held on April 23, 2026. A total of 209,777,472 shares of common stock were represented in person or by proxy out of 223,568,966 shares outstanding and entitled to vote as of the record date.
Stockholders elected nine directors to one-year terms, with each nominee receiving more votes "For" than "Against." They also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026.
Stockholders approved a non-binding advisory resolution on named executive officer compensation, and two stockholder proposals—one requesting a report on healthcare consequences and another on shareholders’ right to act by written consent—did not receive sufficient support for approval.
HCA Healthcare, Inc. announced that its wholly owned subsidiary, HCA Inc., plans a public offering of senior unsecured notes, with final terms such as maturity, interest rate and principal amount to be set at pricing. The notes will be issued under an effective shelf registration.
HCA Inc. has given notice to redeem all $1.500 billion of its 5.250% senior notes due June 2026 and all $1.000 billion of its 5.375% senior notes due September 2026 on May 27, 2026, subject to receiving net proceeds from the new offering. HCA Inc. intends to use net proceeds for general corporate purposes, which may include repaying borrowings under its $4.000 billion commercial paper program and redeeming some or all of these 2026 notes.